Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

92.92 -0.01 (-0.01%)

Official Closing Price Updated: 4:10 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical

October 01, 2024

From Merck & Co., Inc.

Via Business Wire

Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31

October 01, 2024

From Merck & Co., Inc.

Via Business Wire

2 High-Potential Growth Stocks You Shouldn't Overlook ↗

September 29, 2024

These two growth stocks have plenty of room to run.

Via The Motley Fool

Is Merck Stock a Buy? ↗

September 29, 2024

There is mounting pressure on the company's most prized franchise.

Via The Motley Fool

Evaxion Biotech Partners With Merck To Expand Vaccine Development ↗

September 26, 2024

Evaxion Biotech enters an expanded collaboration with Merck, granting an option to license preclinical vaccine candidates. The deal includes $3.2 million upfront and potential earnings up to $592...

Via Benzinga

This Is What Whales Are Betting On Merck & Co ↗

September 25, 2024

Via Benzinga

Merck & Co Unusual Options Activity For September 23 ↗

September 23, 2024

Via Benzinga

Exploring NYSE:MRK's dividend characteristics. ↗

September 20, 2024

Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK).

Via Chartmill

Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024

September 26, 2024

From Merck & Co., Inc.

Via Business Wire

FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients ↗

September 25, 2024

The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers.

Via Benzinga

Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years ↗

September 25, 2024

Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and...

Via Benzinga

Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study ↗

September 25, 2024

Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve overall survival compared to standard treatments, though safety remained...

Via Benzinga

Behind the Scenes of Merck & Co's Latest Options Trends ↗

September 18, 2024

Via Benzinga

NYSE:MRK: good value for what you're paying. ↗

September 18, 2024

MERCK & CO. INC. (NYSE:MRK) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry ↗

September 17, 2024

Via Benzinga

Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer

September 25, 2024

From Merck & Co., Inc.

Via Business Wire

Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma

September 25, 2024

From Merck & Co., Inc.

Via Business Wire

Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus

September 24, 2024

From Merck & Co., Inc.

Via Business Wire

Pfizer Advances On Its Cancer Journey ↗

September 20, 2024

On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024...

Via Benzinga

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

September 20, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END

Via FinancialNewsMedia

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

September 20, 2024

From FN Media Group LLC

Via GlobeNewswire

Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers

September 20, 2024

From Merck & Co., Inc.

Via Business Wire

Is It Too Late to Buy ServiceNow Stock? ↗

September 20, 2024

The stock is up nearly 60% since the beginning of the year.

Via The Motley Fool

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Via Investor's Business Daily

Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer ↗

September 18, 2024

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line treatment of advanced or metastatic malignant pleural mesothelioma.

Via Benzinga

This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous. ↗

September 18, 2024

There's a lot of hope for ivonescimab, but are investors being a bit too bullish?

Via The Motley Fool

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)

September 18, 2024

From Merck & Co., Inc.

Via Business Wire

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030 ↗

September 18, 2024

These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.

Via The Motley Fool

How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery ↗

September 17, 2024

BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.

Via Investor's Business Daily

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study ↗

September 17, 2024

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival...

Via Benzinga

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Merck & Co (NY:MRK)

All News about Merck & Co

Starting at $3.75/week.

Subscribe Today